These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28813448)

  • 21. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
    Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
    J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease.
    Fujiwara Y; Kuroda H; Abe T; Ishida K; Oguri T; Noguchi S; Sugai T; Kamiyama N; Takikawa Y
    Ultrasound Med Biol; 2018 Nov; 44(11):2223-2232. PubMed ID: 30077415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
    Yen YH; Chen JF; Wu CK; Lin MT; Chang KC; Tseng PL; Tsai MC; Lin JT; Hu TH
    J Formos Med Assoc; 2017 Nov; 116(11):852-861. PubMed ID: 28888355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Mendes LC; Ferreira PA; Miotto N; Zanaga L; Lazarini MS; Gonçales ESL; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):959-966. PubMed ID: 29727388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
    de Lédinghen V; Hiriart JB; Vergniol J; Merrouche W; Bedossa P; Paradis V
    Dig Dis Sci; 2017 Sep; 62(9):2569-2577. PubMed ID: 28577247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
    de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
    J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of controlled attenuation parameter in a health check-up cohort.
    Kwak MS; Chung GE; Yang JI; Yim JY; Chung SJ; Jung SY; Kim JS
    Liver Int; 2018 May; 38(5):915-923. PubMed ID: 28940824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
    Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter.
    Yen YH; Kuo FY; Lin CC; Chen CL; Chang KC; Tsai MC; Hu TH
    Transplant Proc; 2018 Dec; 50(10):3533-3538. PubMed ID: 30577232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?
    Chan WK; Nik Mustapha NR; Mahadeva S; Wong VW; Cheng JY; Wong GL
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1787-1794. PubMed ID: 29603365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique.
    Bae JS; Lee DH; Lee JY; Kim H; Yu SJ; Lee JH; Cho EJ; Lee YB; Han JK; Choi BI
    Eur Radiol; 2019 Dec; 29(12):6499-6507. PubMed ID: 31175413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.
    Sviklāne L; Olmane E; Dzērve Z; Kupčs K; Pīrāgs V; Sokolovska J
    J Gastroenterol Hepatol; 2018 Jan; 33(1):270-276. PubMed ID: 28464337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility based multiparametric quantification of liver disease: Non-invasive evaluation of steatosis and iron overload.
    Uhrig M; Mueller J; Longerich T; Straub BK; Buschle LR; Schlemmer HP; Mueller S; Ziener CH
    Magn Reson Imaging; 2019 Nov; 63():114-122. PubMed ID: 31425813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection.
    Hirche TO; Ignee A; Hirche H; Schneider A; Dietrich CF
    Liver Int; 2007 Aug; 27(6):748-57. PubMed ID: 17617117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study.
    Yoo JJ; Yoo YJ; Moon WR; Kim SU; Jeong SW; Park HN; Park MG; Jang JY; Park SY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SG; Kim YS; Kim JH; Yeon JE; Byun KS
    Korean J Intern Med; 2020 Nov; 35(6):1346-1353. PubMed ID: 31694366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
    Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.